Product features

Inactivated Epstein Barr virus (EBV) formulated in human plasma specimen.

  • External quality control for nucleic acids detection
  • Validation of the complete analytical process: extraction & amplification
  • Complete inactivated microorganism in a matrix
  • Quantified controls (low positive)
  • 10 single-use lyophilized vials 

 

> Further information available for the design of primers and probes: 
· Complete genome:Epstein-Barr virus V01555.2

Kit AMPLIRUN TOTAL

PRODUCTS

AMPLIRUN® TOTAL EBV CONTROL (PLASMA)

RUO
Inactivated Epstein Barr virus (EBV) formulated in human plasma specimen and intended to validate and control sample processing, analysis and detection in nucleic acid assays using the product as an external run control.
Reference MBTC019-R
Pack size 10 vials
Volume 200 μL

HOW IT WORKS

amplirun total how does it work

MORE RESOURCES

Virus/Bacterias
RELATED VIRUSES/BACTERIA

Related germs and organisms categorized for this product line.

Blog
BLOG

The latest insights, news, and research articles from our scientific team.

Infecciones vaginales polimicrobianas: por qué importan los controles de terceros en diagnóstico molecular
02 July 2026

Infecciones vaginales polimicrobianas: por qué importan los controles de terceros en diagnóstico molecular

Understanding the complexity of vaginal infectionsVaginal infections are among the most frequent reasons for gynecological consultation, but their dia...

Beyond detection: H. pylori testing in today’s laboratory workflow
26 June 2026

Beyond detection: H. pylori testing in today’s laboratory workflow

Helicobacter pylori remains a highly relevant target in gastrointestinal diagnostics. It is a familiar pathogen, but its clinical importance has not d...

Aspergillus galactomannan: a practical biomarker for invasive aspergillosis diagnosis
15 May 2026

Aspergillus galactomannan: a practical biomarker for invasive aspergillosis diagnosis

Invasive aspergillosis is still one of the most difficult fungal infections to diagnose early. It mainly affects patients with weakened immune systems...